Trial
NCT04756765
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Stanford University
Collaborators
Pfizer
Condition
Breast Cancer
Intervention
Talazoparib Tosylate
Why stopped
Due to changes in the treatment landscape, the study faced significant recruitment challenges. As no patients were enrolled, the sponsor requested study closure
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-17